In glioblastoma (GBM), epithelial growth factor receptor (EGFR) vIII‐activated, PI3K/sterol regulatory element‐binding protein (SREBP) 1‐dependent LDLR upregulation was shown to promote GBM cell survival, while targeting LDLR using nuclear liver‐X‐receptor (LXR) agonists has shown therapeutic value for GBM patients.30 This evidence concerns the gene EGFR and glioblastoma.